The European stock market has recently experienced a boost, with the pan-European STOXX Europe 600 Index reaching record levels amid a rally in technology stocks and expectations for lower U.S. borrowing costs. This positive momentum creates an intriguing backdrop for investors exploring opportunities in smaller or newer companies, often referred to as penny stocks. Although the term 'penny stock' might seem outdated, these investments can still offer significant growth potential when backed by solid financials and fundamentals.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.07 | €1.41B | ✅ 5 ⚠️ 2 View Analysis > |
| Lucisano Media Group (BIT:LMG) | €1.14 | €16.94M | ✅ 4 ⚠️ 4 View Analysis > |
| Maps (BIT:MAPS) | €3.24 | €43.03M | ✅ 4 ⚠️ 1 View Analysis > |
| DigiTouch (BIT:DGT) | €1.975 | €26.91M | ✅ 3 ⚠️ 1 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €227.95M | ✅ 2 ⚠️ 2 View Analysis > |
| Hove (CPSE:HOVE) | DKK4.41 | DKK111.5M | ✅ 2 ⚠️ 2 View Analysis > |
| Siili Solutions Oyj (HLSE:SIILI) | €4.84 | €39.25M | ✅ 3 ⚠️ 3 View Analysis > |
| Hifab Group (OM:HIFA B) | SEK3.42 | SEK208.07M | ✅ 2 ⚠️ 2 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.09 | €288.88M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 270 stocks from our European Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Vivoryon Therapeutics (ENXTAM:VVY)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Vivoryon Therapeutics N.V. is a clinical stage biopharmaceutical company dedicated to the research, development, and commercialization of small molecule-based medicines, with a market cap of €42.81 million.
Operations: Vivoryon Therapeutics N.V. does not currently report any revenue segments as it is focused on the research, development, and commercialization of small molecule-based medicines.
Market Cap: €42.81M
Vivoryon Therapeutics is a pre-revenue biopharmaceutical company with a market cap of €42.81 million, focusing on small molecule-based medicines. Despite its unprofitability, the company's net loss has decreased significantly from €13.56 million to €5.47 million year-over-year for the half year ended June 30, 2025. The firm is debt-free and has short-term assets exceeding both its short and long-term liabilities, suggesting some financial stability despite having less than a year of cash runway. The management team is experienced with an average tenure of 4.7 years; however, the board's inexperience may be a concern for potential investors in this volatile penny stock sector.
- Get an in-depth perspective on Vivoryon Therapeutics' performance by reading our balance sheet health report here.
- Evaluate Vivoryon Therapeutics' prospects by accessing our earnings growth report.
Aiforia Technologies Oyj (HLSE:AIFORIA)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Aiforia Technologies Oyj, along with its subsidiary Aiforia Inc., offers AI-based image analysis software for clinical, preclinical, and academic laboratories globally, with a market cap of €87.87 million.
Operations: The company generates revenue from its healthcare software segment, amounting to €2.88 million.
Market Cap: €87.87M
Aiforia Technologies Oyj, with a market cap of €87.87 million, is gaining attention through strategic partnerships and innovative AI solutions in the healthcare sector. Recent collaborations with Siemens Healthineers and Dedalus Group aim to enhance diagnostic precision and expand their reach across Europe. Despite these promising developments, Aiforia remains unprofitable with a net loss of €6.62 million for H1 2025 and has less than a year of cash runway. The company's revenue stands at €2.88 million from its healthcare software segment, while its short-term assets exceed liabilities, indicating some financial resilience amidst volatility in share price.
- Click here and access our complete financial health analysis report to understand the dynamics of Aiforia Technologies Oyj.
- Gain insights into Aiforia Technologies Oyj's outlook and expected performance with our report on the company's earnings estimates.
IMS (WSE:IMS)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: IMS S.A., along with its subsidiaries, primarily offers sensory marketing services in Poland and has a market capitalization of PLN105.82 million.
Operations: The company generates revenue from various segments, including PLN10.50 million from Subscription Fees Aroma, PLN32.87 million from Audio and Video Subscriptions, and PLN21.64 million from Audio and Video Advertising Services.
Market Cap: PLN105.82M
IMS S.A., with a market cap of PLN105.82 million, shows mixed financial health in the penny stock landscape. While earnings are forecasted to grow annually by 9.96%, recent results indicate declining net income, with PLN2.7 million for H1 2025 compared to PLN4.87 million the previous year. The company maintains satisfactory debt levels, with a net debt to equity ratio of 38.1%, and its interest payments are well covered by EBIT at seven times coverage. Despite trading below estimated fair value, IMS faces challenges in covering short-term liabilities and sustaining dividends through free cash flow amidst stable weekly volatility.
- Unlock comprehensive insights into our analysis of IMS stock in this financial health report.
- Gain insights into IMS' future direction by reviewing our growth report.
Next Steps
- Get an in-depth perspective on all 270 European Penny Stocks by using our screener here.
- Ready For A Different Approach? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Aiforia Technologies Oyj might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com